Abstract
Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that ‘polyvalent’ vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole exome sequencing (WES) and RNA sequencing (RNA-Seq). Fifty-eight tumor samples from 57 patients with FL underwent WES and RNA-Seq. Somatic and B-cell clonotype neoantigens were predicted and filtered to identify high-quality neoantigens. B-cell clonality was determined by alignment of B-cell receptor (BCR) CDR3 regions from RNA-Seq data, grouping at the protein level, and comparison to the BCR repertoire of RNA-Seq data from healthy individuals. An average of 52 somatic mutations per patient (range: 2-172) were identified, and two or more (median: 15) high-quality neoantigens were predicted for 56 of 58 samples. The predicted neoantigen peptides were composed of missense mutations (76%), indels (9%), gene fusions (3%), and BCR sequences (11%). Building off of these preclinical analyses, we initiated a pilot clinical trial using personalized neoantigen vaccination combined with PD-1 blockade in patients with relapsed or refractory FL (#NCT03121677). Synthetic long peptide (SLP) vaccines were successfully synthesized for and administered to all four patients enrolled to date. Initial results demonstrate feasibility, safety, and potential immunologic and clinical responses. Our study suggests that a genomics-driven personalized cancer vaccine strategy is feasible for patients with FL, and this may overcome prior challenges in the field.
Competing Interest Statement
Neha Mehta-Shah has served as a consultant for Kyowa Hakka Kirin, Daiichi Sankyo, Karyopharm Therapeutics, C4 Therapeutics. She has institutional research funding from Celgene, Bristol-Myers Squibb, Verastem, Innate Pharmaceuticals, Corvus Pharmaceuticals, Genentech/Roche. Felix Frenkel, Olga Kudryashova, Vladislav Belousov, Alexander Bagaev, Elena Ocheredko and Ravshan Ataullakhanov are full time employees of BostonGene Corporation. Nancy L. Bartlett has research funding from ADC Therapeutics, Affimed, Autolous, Bristol-Meyers Squibb, Celgene, Forty Seven Immune Design, Janssen, Kite Pharm, Merk, Millennium, Pfizer, Pharmacyclics, Roche/Genentech and SeaGen and has been on the advisory board for ADC Therapeutics, Roche/Genentech, SeaGen, BTG and Acerta. Todd A. Fehniger has research funding from ImmunityBio, Affimed, Wugen, and HCW Biologics; consults for Wugen, GamidaCell, Takeda, Nkarta, Indapta, Orca Bio; and has equity and potential royalty interest in Wugen. The remaining authors declare no competing financial interests.
Clinical Trial
NCT03121677
Funding Statement
This work was supported by the Michael and Ena Feinberg Lymphoma Research Fund, the Jamie Erin Follicular Lymphoma Research Consortium, the Steinback fund of the Barnes Jewish Hospital Foundation, and the Alvin J. Siteman Cancer Center Siteman Investment Program (supported by The Foundation for Barnes-Jewish Hospital, Cancer Frontier Fund and Barnard Trust). We also thank the Siteman Cancer Center at Washington University School of Medicine for the use of the Siteman Flow Cytometry Core, which provided cell sorting service and the Bursky Center for Human Immunology and Immunotherapy Immunomonitoring Laboratory. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant P30CA091842. Obi Griffith was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) on awards U01CA209936, U01CA231844, U24CA237719, and U01CA248235. Malachi Griffith was supported by the National Human Genome Research Institute (NHGRI) of the NIH under award R00HG007940, the NCI under awards U01CA209936, U01CA231844, U24CA237719 and U01CA248235, and the V Foundation for Cancer Research under award V2018-007.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Washington University Institutional Review Board of Washington University in St. Louis gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data have been deposited in dbGaP (accession: phs001229).
